British Columbia Adds Renflexis, a Remicade Biosimilar for Crohn’s, UC, to Public Drug Plan

British Columbia Adds Renflexis, a Remicade Biosimilar for Crohn’s, UC, to Public Drug Plan
Renflexis (infliximab-abda), Merck’s biosimilar of Remicade (infliximab), has been added to the public drug plan of the Canadian province of British Columbia. As of Aug. 21, adults and children with Crohn’s disease and ulcerative colitis, as well as other approved indications, can now be reimbursed for the costs associated with Renflexis treatment. “We are pleased to

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *